Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020068873 - TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE

Publication Number WO/2020/068873
Publication Date 02.04.2020
International Application No. PCT/US2019/052790
International Filing Date 24.09.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 403/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 491/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
08Bridged systems
A61K 31/498 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
498Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 491/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • BLACK DIAMOND THERAPEUTICS, INC. [US]/[US]
  • FLOHR, Alexander [CH]/[CH]
  • MAYWEG, Alexander [US]/[US]
  • TRAINOR, George [US]/[US]
  • EPSTEIN, David M. [US]/[US]
  • O'CONNOR, Matthew [US]/[US]
  • BUCK, Elizabeth [US]/[US]
Inventors
  • FLOHR, Alexander
  • MAYWEG, Alexander
  • TRAINOR, George
  • EPSTEIN, David M.
  • O'CONNOR, Matthew
  • BUCK, Elizabeth
Agents
  • ERLACHER, Heidi A.
  • ELRIFI, Ivor
  • SUN, Xixi
Priority Data
62/736,29125.09.2018US
62/903,59820.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
(FR) COMPOSITIONS D'INHIBITEUR DE TYROSINE KINASE, PROCÉDÉS DE FABRICATION ET PROCÉDÉS D'UTILISATION
Abstract
(EN)
The present disclosure relates to new compounds of formula I and pharmaceutically acceptable salts and stereoisomers thereof, as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, (e.g., humans).
(FR)
La présente invention concerne de nouveaux composés de formule I et des sels pharmaceutiquement acceptables et des stéréo-isomères de ceux-ci, utilisés comme inhibiteurs des récepteurs à activité tyrosine kinase (RTK), en particulier des mutants extracellulaires de récepteurs ErbB. L'invention concerne également des procédés de préparation de ces composés, des compositions comprenant ces composés, et des procédés d'utilisation de ceux-ci dans le traitement d'une croissance cellulaire anormale chez des mammifères (par exemple, des êtres humains).
Latest bibliographic data on file with the International Bureau